Collectively, we demonstrated that SETD2 deficiency results in large-scale metabolic reprogramming and de novo SM biosynthesis, thereby accelerating the transition from PKD to ccRCC. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.